GRACELL BIOTECHNOLOGIES-ADR(NASDAQ:GRCL) stock News

GRCL Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Gracell Biotechnologies Inc.

亘喜生物宣布正式并入阿斯利康集团

2 years ago - By: Gracell Biotechnologies Inc.

Gracell Biotechnologies Acquisition Completed

2 years ago - By: Gracell Biotechnologies Inc.

Gracell Biotechnologies Acquisition Completed

2 years ago - By: Gracell Biotechnologies Inc.

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement

2 years ago - By: Benzinga - Mentions: AZN

Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies

2 years ago - By: Gracell Biotechnologies Inc.

亘喜生物宣布公司股东正式投票表决通过了与阿斯利康的并购协议

2 years ago - By: Gracell Biotechnologies Inc.

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement

2 years ago - By: Gracell Biotechnologies Inc.

亘喜生物宣布FasTCAR-T GC012F早线治疗多发性骨髓瘤的1期新药临床试验（IND）申请获美国FDA批准

2 years ago - By: Gracell Biotechnologies Inc.

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

2 years ago - By: Gracell Biotechnologies Inc.

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

2 years ago - By: Benzinga - Mentions: GILD AZN BMY JNJ ...

Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment

2 years ago - By: Brodsky & Smith LLC - Mentions: AMAM JNJ AZN AXNX ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

2 years ago - By: Brodsky & Smith LLC - Mentions: AMAM JNJ AZN AXNX ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

2 years ago - By: Investor's Business Daily - Mentions: LLY ARWR XBI BMY ...

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

2 years ago - By: Brodsky & Smith LLC - Mentions: RYZB DSKE KRTX BMY ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

2 years ago - By: Kahn Swick & Foti, LLC

GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL

2 years ago - By: Investor's Business Daily - Mentions: TSLA BMY LI NIO ...

Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review

2 years ago - By: Brodsky & Smith LLC - Mentions: BMY RYZB DSKE KRTX ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

2 years ago - By: Halper Sadeh LLC

GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders

2 years ago - By: Bloomberg

GRACELL BIOTECHNOLOGIES-ADR (GRCL) Stock News

GRCL Latest News, Press Relases and Analysis

亘喜生物宣布正式并入阿斯利康集团

Gracell Biotechnologies Acquisition Completed

Gracell Biotechnologies Acquisition Completed

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement

Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies

亘喜生物宣布公司股东正式投票表决通过了与阿斯利康的并购协议

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement

亘喜生物宣布FasTCAR-T GC012F早线治疗多发性骨髓瘤的1期新药临床试验（IND）申请获美国FDA批准

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL

Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders

AstraZeneca to Buy Cancer Drug Developer for Up to $1.2 Billion